Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Precigen's peak revenue was $219.5M in 2017. The peak quarterly revenue was $65.5M in 2017(q4).
Precigen's revenue increased from $800.0k in 2012 to $3.9M currently. That's a 390.63% change in annual revenue.
| Fiscal year / year | Precigen revenue |
|---|---|
| 2012 | $800,000 |
| 2013 | $800,000 |
| 2014 | $1.4M |
| 2015 | $4.3M |
| 2016 | $190.9M |
| 2017 | $219.5M |
| 2018 | $151.2M |
| 2019 | $90.7M |
| 2020 | $32.0M |
| 2021 | $14.3M |
| 2022 | $26.9M |
| 2023 | $6.2M |
| 2024 | $3.9M |
Rate Precigen's financial transparency
Precigen saw the greatest revenue growth in 2016, when revenue increased by 4,307.34%.
Precigen had the lowest revenue growth in 2020, when revenue changed by -64.74%.
| Year | Precigen growth |
|---|---|
| 2013 | 0%↓ |
| 2014 | 72%↑ |
| 2015 | 216%↑ |
| 2016 | 4307%↑ |
| 2017 | 15%↑ |
| 2018 | -31%↓ |
| 2019 | -40%↓ |
| 2020 | -65%↓ |
| 2021 | -55%↓ |
| 2022 | 89%↑ |
| 2023 | -77%↓ |
| 2024 | -37%↓ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | $53.7M | $54.4M | $46.0M | $65.5M |
| 2018 | $39.7M | $45.3M | $32.4M | $33.8M |
| 2019 | $22.6M | $32.8M | $18.3M | ($41.7M) |
| 2020 | $29.8M | $30.4M | $23.6M | $19.4M |
| 2021 | $24.5M | $3.8M | $3.3M | $3.7M |
| 2022 | $5.5M | $2.9M | $16.7M | $1.8M |
| 2023 | $1.9M | $1.8M | $1.4M | $1.2M |
| 2024 | $1.1M | $717,000 | $953,000 | $1.2M |
Do you work at Precigen?
Is Precigen transparent about its revenue structure?
| CEO | Christopher Rogers |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 882 |
| Date Founded | 1998 |
| Headquarters | Germantown, Maryland |
| Number of Locations | 2 |
| Revenue | $3.9M |
| Net Income | $28,317,000 |
| Gross Proft | ($342.0K) (2024) |
| Tax Rate | 0.0% |
| Total Assets | $215,977,000 |
| Ticker | PGEN |
Precigen received early financing of $500.0K on 2005-05-17.
| Series | Round size | Date |
|---|---|---|
| Series B | $500K | 05/2005 |
| Series Unknown | $1M | 03/2006 |
| Series C | $25M | 05/2007 |
| Series C | $10M | 07/2009 |
| Series D | $17.4M | 03/2010 |
| Series E | $100M | 05/2011 |
| Series F | $150M | 05/2013 |
| Post Ipo Equity | $57.5M | 01/2015 |
| Post Ipo Equity | $35M | 02/2020 |
| Post Ipo Equity | $129.4M | 01/2021 |
| Investors | Security type |
|---|---|
| Third Security LLC | Series B |
| NewVa Capital Partners | Series Unknown |
| Third Security LLC | Series C |
| Randal J Kirk | Series E |
| Third Security LLC | Series E |
| NewVa Capital Partners | Series E |
| Randal J Kirk | Series F |
| Third Security LLC | Series F |
Precigen's top competitor, Alphabet, earned an annual revenue of $350.0B.
Precigen's smallest competitor is CFA Institute with revenue of $168.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 340 |
| Amgen | $93,349 | $33.4B | 22,000 | 653 |
| Morgan Stanley | $103,933 | $3.0B | 68,097 | 1,051 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,777 |
| Merck | $90,328 | $64.2B | 74,000 | 1,729 |
| Alphabet | $58,794 | $350.0B | 156,301 | - |
| Bain & Company | $89,339 | $4.5B | 10,500 | 97 |
| CFA Institute | $102,363 | $168.0M | 2,446 | 16 |
| Elevance Health | $59,054 | $121.9B | 63,900 | 3 |
Zippia gives an in-depth look into the details of Precigen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Precigen. The employee data is based on information from people who have self-reported their past or current employments at Precigen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Precigen. The data presented on this page does not represent the view of Precigen and its employees or that of Zippia.
Precigen may also be known as or be related to PRECIGEN, INC., Precigen, Precigen Inc and Precigen, Inc.